More critical than ever - @NCICancer @PeterMacCC #TxID Innovation in active and passive immunisation of people who are immunocompromised: a call to action - The Lancet Infectious Diseases

Management of Clostridioides difficile infection in patients with haem... https://t.co/m3CJpJ3Mfi Delighted to have been part of a lovely team of experts! #TxID

Influenza-Specific T-Cell Responses to Vaccination Are Independent of Underlying Hematological Malignancy: Analysis of a Randomized Influenza Vaccination Trial

Grateful to haem cancer consumers for their guidance. #TxID Recommendations for innovation in vaccination services for adults with...

Optimal vaccination is challenging - especially in ICH pts! New @NEJM @victoriahall26 study assessing flu vax in heme pts: two-dose adjuvanted v standard 💉 Similar seroconversion 💉 Better response in MM, though similar between arms Find it in vax 📁! https://t.co/oHOv4lNl8s

Very proud of this hard work by all involved. Limited benefit of adjuvanted flu vaccine vs standard dose and 2 vs 1 doses in patients with myeloma, CLL or NHL. @NEJM @PeterMacCC @NCICancer

In this trial involving patients with hematologic cancers, the immune responses that were elicited were similar for adjuvanted-dose and standard-dose influenza vaccines. Read the full trial results: https://t.co/idoSst4fkx

Poster presentations in session… presenting influenza-specific B & T cell analyses in pts w/ haematological malignancy - T cell responses preserved & less dependent on underlying disease and treatment regimen received. @NCICancer @kedzierskalab @id_austin @benwteh @options2024

Delighted to be part of @NCICancer @monicaslavin CRE to reduce the burden of infection in patients on new gen therapies.

Congratulations to the 20 new NHMRC’s Centres of Research Excellence that will share in an investment of $60 million announced today. Read our media release on our News Centre: https://t.co/Za779vgxbn

Peter Mac has been awarded 3 significant @nhmrc grants totalling $9m to drive forward innovative approaches in #cancer treatment, lymphatic health and antimicrobial stewardship, led by @BenjaminHogan13, @monicaslavin and Prof Karin Thursky. More 👇 https://t.co/ENdaGmvpcW

Wonderful work by @GemmaKReynolds queen of systematic rev and meta-analysis!

A global call to encourage the use of standard reporting of infection AEs so we can advance research in the field. It was also mentioned at #ESCMIDGlobal2024

Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis [Oct 10, 2023] @GemmaKReynolds et al. @benwteh @BloodAdvances https://t.co/k1uPIqIOD6 #IDonc #mmsm #caxtx

#ECCMID2024 Hot topic 🔥 of developing AI tools for infection detection. Anna Khanina @NCICancer @NCAS_Aus explaining the laborious manual process and aiming for AI detection. Check out this cool dashboard for fungal infections IFIS!!! Coming soon

#ECCMID2024 Results from RCT of SD vs AD flu vaccine as a strategy for high-risk HM group by @victoriahall26 @NCICancer @benwteh showing no difference in primary outcome seroconversion but highlighting the CLL NHL groups as having poor responses in general. How to improve this?

Hot off the press - late breaking data from @victoriahall26 @NCICancer demonstrating similiar immunogenicity from two different vax strategies and no incremental benefit of second dose. #ESCMIDGlobal2024 #TxID

An amazing nation wide randomised trial of a simple reminder transforming vaccination uptake, even in immune compromised. Elegant solution. #ESCMIDGlobal2024 #TxID

Thanks for coming to our session. @NATBASH15 and i had fun with our talks. Hope it was useful! #ESCMIDGlobal2024 #TxID

Superb and hard work from @victoriahall26 PhD extraordinaire. Another impactful collab with @kedzierskalab . Will guide future long acting MoAb Prep practice. #TxID